Cytek Biosciences (CTKB) Stock Forecast: StockMap's 2-Week Call
CTKB stock forecast: StockMap's model leans Outperform on Cytek Biosciences for the two weeks after the Nov 19 close, toward CTKB doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 5 two-week windows on CTKB since Aug 21; by chance, a call on the same dates was right 67% of the time.
Cytek Biosciences last closed at $6.32, +6.76% on the session.
Against the IVW growth benchmark the position is +9.09% over the forecast window.
Cytek Biosciences' market cap is $826.58M as of November 19, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 27 (too close to call).
Where CTKB sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 33%.
34 daily calls for CTKB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Cytek Biosciences in the 25th percentile on return on equity, where 100 is best.
Cytek Biosciences is classified under Health Care / Life Sciences Tools & Services.
StockMap tracks Cytek Biosciences as the 31st largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.
Across that group the current two-week reads are 23 Neutral, 16 Moderate Outperform and 3 Moderate Underperform.
On that composite Cytek Biosciences ranks 10th of 42 in the group, against a group median of +0.13.